FIG 3.
Immune-mediated adverse events at 3 years (September 6, 2016) and at 5 years (November 5, 2018) of follow-up. Immune-mediated AEs were classified based on a list of preferred terms identified by the sponsor as having an immune etiology. Because there were changes in events included in this list between the 3- and 5-year analyses, certain events classified as immune-mediated at 3 years may not have been so-classified at 5 years.